Study of Zanidatamab with chemo before surgery for HER2+ stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new targeted drug called zanidatamab given with standard chemotherapy before surgery for HER2-positive stomach or gastroesophageal junction cancer. It aims to shrink the tumor enough to allow successful removal, either for cancers that were initially too advanced for surgery or for those with high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that is HER2-positive (IHC 3+ or 2+ with a positive FISH test).
- Your cancer is either stage III with a high risk of spread, locally advanced and not removable right away, or has spread to just a few places like the liver or lymph nodes.
- You are between 18 and 75 years old.
- You are in good enough health to have surgery (ECOG score 0 or 1) and your organs are working well.
- You have not had prior systemic therapy for your stomach cancer (if in the neoadjuvant group).
- You do not have other active cancers, serious infections, or uncontrolled health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
This study observes people with advanced HER2-positive stomach or esophageal cancer who are starting a treatment that includes zanidatamab. It collects information about their experiences and quality of life during treatment.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests a new drug called zanidatamab combined with standard chemotherapy before surgery for HER2-positive stomach or gastroesophageal junction cancer. It aims to shrink the tumor and improve outcomes.
This trial tests adding zanidatamab (an antibody targeting HER2) to standard chemotherapy before and after surgery for operable HER2-positive stomach or esophagus cancer. It aims to see if this combination improves outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.